期刊
MUCOSAL IMMUNOLOGY
卷 7, 期 1, 页码 89-100出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/mi.2013.27
关键词
-
类别
资金
- Medical Research Council Clinical Research Training Fellowship
- Medical Research Council [G0501446, G0900950, G0900950B, G0900374, G9721629, G9721629B] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0512-10124] Funding Source: researchfish
- MRC [G0900374] Funding Source: UKRI
Vaccines that induce T cells, which recognize conserved viral proteins, could confer universal protection against seasonal and pandemic influenza strains. An effective vaccine should generate sufficient mucosal T cells to ensure rapid viral control before clinical disease. However, T cells may also cause lung injury in influenza, so this approach carries inherent risks. Here we describe intranasal immunization of mice with a lentiviral vector expressing influenza nucleoprotein (NP), together with an NFjB activator, which transduces over 75% of alveolar macrophages (AM). This strategy recalls and expands NP-specific CD8+ T cells in the lung and airway of mice that have been immunized subcutaneously, or previously exposed to influenza. Granzyme B-high, lung-resident T-cell populations persist for at least 4 months and can control a lethal influenza challenge without harmful cytokine responses, weight loss, or lung injury. These data demonstrate that AM can be harnessed as effective antigen-presenting cells for influenza vaccination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据